FibroGen (NASDAQ:FGEN) Coverage Initiated by Analysts at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of FibroGen (NASDAQ:FGEN) in a report released on Monday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Separately, William Blair reiterated a “market perform” rating on shares of FibroGen in a research note on Wednesday, November 13th.

FibroGen Price Performance

Shares of FibroGen stock opened at $0.33 on Monday. FibroGen has a 1-year low of $0.18 and a 1-year high of $2.93. The business has a 50-day moving average of $0.35 and a 200-day moving average of $0.59. The company has a market capitalization of $33.55 million, a PE ratio of -0.27 and a beta of 0.82.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) EPS for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.21. The company had revenue of $46.33 million for the quarter, compared to the consensus estimate of $34.00 million. During the same quarter last year, the company earned ($0.52) earnings per share. On average, equities analysts expect that FibroGen will post -0.86 earnings per share for the current fiscal year.

Institutional Trading of FibroGen

A number of large investors have recently modified their holdings of the company. Acadian Asset Management LLC boosted its position in FibroGen by 34.4% during the 2nd quarter. Acadian Asset Management LLC now owns 3,364,719 shares of the biopharmaceutical company’s stock worth $2,997,000 after acquiring an additional 860,854 shares during the period. Doheny Asset Management CA bought a new position in FibroGen during the 2nd quarter valued at $48,000. XTX Topco Ltd acquired a new position in shares of FibroGen during the 2nd quarter valued at $424,000. Sei Investments Co. raised its stake in shares of FibroGen by 38.4% in the 2nd quarter. Sei Investments Co. now owns 149,342 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 41,442 shares in the last quarter. Finally, Point72 DIFC Ltd lifted its holdings in FibroGen by 734.2% in the 2nd quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock valued at $47,000 after acquiring an additional 45,990 shares during the last quarter. Institutional investors and hedge funds own 72.71% of the company’s stock.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.